either as a monotherapy or in combination with immune checkpoint inhibitors such as PD-1 or PD-L1 inhibitors. Other than oncology, the unique MOA as a metabolic regulator also shows the potential ...

Nanobiotix announces full results from completed phase 1 study evaluating JNJ-1900 (NBTXR3) in pancreatic cancer: Paris Tuesday, May 6, 2025, 11:00 Hrs [IST] Nanobiotix, a late-st ...

Given the physical MoA, Nanobiotix believes that NBTXR3 ... and across any therapeutic combination, particularly immune checkpoint inhibitors. Radiotherapy-activated NBTXR3 is being evaluated ...

Given the physical MoA, Nanobiotix believes that JNJ-1900 ... and across any therapeutic combination, particularly immune checkpoint inhibitors. Radiotherapy-activated JNJ-1900 (NBTXR3) is ...

IO Biotech's first-in-class vaccine performs double duty, killing cancer cells and enhancing the tumor microenvironment. A ...

Older patients have divergent immune phenotypes at baseline that persist during immune checkpoint inhibitor therapy.

Inflammatory arthritis as a result of immune checkpoint cancer therapy remains a pressing challenge for patients and ...

Targeting the intracellular immune checkpoint CISH with CRISPR-Cas9-edited tumor-infiltrating lymphocytes (TILs) may be ...

Older patients have divergent immune phenotypes at baseline that persist during immune checkpoint inhibitor therapy. HealthDay News — Patients with cancer aged 65 years and older receiving ...